



## BIOTECH SUPPORT GROUP

### Cleanascite™


#### *Lipid adsorption and clarification reagent*

- Effectively replaces chlorinated/fluorinated hydrocarbons (eg. freon)
- Workflows for antibodies, proteins, nucleic acids, proteoglycans, and most serum analytes
- A high binding capacity for lipids with minimal cross-reactivity with proteins and nucleic acids
- Ideal for clarifying ascites, serum, cell & tissue culture, bile, saliva, fecal and organ homogenates
- Simple microfuge (not ultra) centrifugation protocols
- Exquisite selectivity profile including extracellular vesicle and exosome clearance
- Compatible with cell response assays
- For bioprocessing, extends the life of membrane and chromatographic columns

**Cleanascite™** selectively removes lipids, cell debris, lipoproteins, floating fats, impurities from Cohn paste, transgenic milk, egg yolk and biological samples for pretreatment of samples prior to purification. The reagent is a solid-phase, non-ionic adsorbent supplied as a suspension in saline, ready for use. Simply add, centrifuge and/or filter. The clarified supernatant is ready for subsequent downstream processing or analysis.

#### Removes Lipid Factors


Phospho-Lipids  
>99% Cholesterol &  
Triglycerides  
Lipoproteins  
Extracellular Vesicles  
(Exosomes)



#### Improved Assay Performance

- ◆ ELISA
- ◆ Immunocapture Microarrays
- ◆ LC-MS
- ◆ Toxin Neutralizing Titer
- ◆ Cell Response

Egg Yolk After (Left) and Before (Right) Treatment With Cleanascite™





## BIOTECH SUPPORT GROUP

Product	Size	Total Sample Volume That Can Be Processed*	Item No.
Cleanascite™	10 ml	40 ml	X2555-10
Cleanascite™	50 ml	200 ml	X2555-50
Cleanascite™	100 ml	400 ml	X2555-100
Cleanascite™	1000 ml	4000 ml	X2555-1000

\*Based on Cleanascite™ to Sample typical volume ratio. Volume ratio may be adjusted according to lipid levels.

### Protocol

Supplied as an aqueous suspension of non-ionic adsorbent in saline, pH 8.0. When not in use, keep sealed. For best results store at 4°C. Do not freeze. **Cleanascite™** retains full activity when stored as directed for at least 6 months.

SAMPLE TYPE (partial list)	Volume Ratio, Cleanascite™ : Sample
General	1 : 5 to 1 : 1
Ascites Fluid	1 : 2 to 1 : 3
Serum, Fetal Calf Serum	1 : 2 to 1 : 3
Lipemic Serum	1 : 2 to 1 : 1
Egg Yolk suspension	1 : 1 to 2 : 1
Tissue homogenates	1 : 4 to 1 : 2

Actual lipid concentration in biological samples can vary greatly, so the ratios shown are only intended to provide general guidance in use.

1. Resuspend **Cleanascite™** by gently shaking. Excessive shaking or mixing will cause foaming. It should be completely resuspended prior to use.
2. Add 1 ml of **Cleanascite™** to 4 ml of the sample (or alternative ratio – see chart above). Mix the sample by gently shaking periodically for 10 minutes.
3. Centrifuge sample at 16,000 G's for 1-2 minutes - or - 2,000 – 3,000 G's for 15 minutes.
4. Decant supernatant containing macromolecules of interest and continue with purification, or analysis.

**Optimization.** Different sample volumes are easily scaled. Volume ratio can be adjusted up or down as required to remove the amount of lipids present.



## BIOTECH SUPPORT GROUP

### Key Reference Applications

#### Cell Response

Albakri, Marwah M., et al. "[Fatty acids secreted from head and neck cancer induce M2-like Macrophages.](#)" *Journal of Leukocyte Biology* (2022).

To assess depletion of fatty acids from tumor supernatants, tumor-conditioned medium was treated with Cleanascite according to the manufacturer's instructions and prior to incubation with monocytes. The article states "**Depletion of Fatty acids with Cleanascite from FaDu or SCC supernatants largely reversed the phenotypic changes in Macrophages otherwise observed by incubating monocytes in these supernatants**".

Yang, X. U. A. N., et al. "[SCD1/FADS2 fatty acid desaturases equipose lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells.](#)" (2021).

The mechanisms underlying ovarian cancer (OvCa) cells dictating their lipid metabolic activities in promoting tumor progression remain elusive. The article states: "**Compared with the negative controls (OCM pretreated with the lipid removal reagent, Cleanascite),** OvCa cells cocultured in the lipid-enriched OCM showed an increase of 18% in membrane fluidity."

Pointner, Lisa, et al. "[Birch pollen induces Toll-like receptor 4-dependent dendritic cell activation favoring T cell responses.](#)" *Frontiers in Allergy* (2021): 42.

The article states "To remove the lipids in birch pollen extracts, Cleanascite™ was used ...according to manufacturer's recommendations ... in a ratio 1:1 (v/v). Importantly, "**non-specific treatment-associated and cytotoxic effects were ruled out ...as neither the protein digestion nor the lipid extraction procedure affected cell activation.**"

Wang, Xueyu, et al. "[Epigenetic Silencing of miR-33b Promotes Peritoneal Metastases of Ovarian Cancer by Modulating the TAK1/FASN/CPT1A/NF-κB Axis.](#)" *Cancers* 13.19 (2021): 4795.

The effective use of Cleanascite™ helped establish that "... **depletion of fatty acids by Cleanascite in OCM significantly impaired ovarian cancer cell migration and invasion.**"

Chen, Rain R., et al. "[Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells.](#)" *Communications Biology* 2 (2019).

The article states: "To determine whether fatty acids in OCM are the primary energy source, fatty acids from OCM was first removed by Cleanascite™ Lipid Removal Reagent... Then, **XTT cell proliferation assays showed that the growth rate of ovarian cancer cells was remarkably reduced in cells cultured in Cleanascite™-treated OCM. Likewise, co-treatment with Cleanascite™ and OCM significantly attenuated the increased cell migration and invasion capacities of ES-2 and SKOV3 cells.**"

Lee, Hong-Jai, et al. "[Regulatory effect of humoral milieu on the viral DNA and surface antigen expression of hepatitis B virus \(HBV\) in vitro.](#)" *Molecular & Cellular Toxicology* 15.2 (2019): 123-128.

**The levels of HBsAg and HBV DNA were significantly decreased with lipid removal by Cleanascite™ in mouse serum rather than human serum.**

#### Monoclonal Antibodies/Ascites

Collecting and Storing Hybridoma Tissue Culture Supernatants  
[doi:10.1101/pdb.prot103317](https://doi.org/10.1101/pdb.prot103317) Cold Spring Harb Protoc 2020.

In the Troubleshooting section, the chapter states: "Problem (Step 7): A precipitate of lipids and/or cryoproteins has formed. Solution: This may be produced by long-term storage at 4°C. **These precipitates can be removed ...using Cleanascite (Biotech Support Group; X2555) for clarification.**"

Shapiro, Scott, et al. "[Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3.](#)" *Infection and immunity* 70.5 (2002): 2598-2604.

"The ascites fluid was collected and centrifuged to remove cells. **Lipids and cell debris were removed with Cleanascite.**"



## BIOTECH SUPPORT GROUP

### Extracellular vesicle clearance/cell response

Nguyen, Doan C., et al. "[Extracellular vesicles from bone marrow-derived mesenchymal stromal cells support ex vivo survival of human antibody secreting cells.](#)" *Journal of extracellular vesicles* 7.1 (2018): 1463778.

**Cleanascite™-treatment of the secretome dramatically reduced ASC functional survival, ... Similar reductions were also noted with the secretome of non-irradiated MSC when treated with Cleanascite™ ..."**

### Bile

Vesterhus, Mette, et al. "[Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.](#)" *Journal of hepatology* 66.6 (2017): 1214-1222.

Lukic, Natalija, et al. "[An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis.](#)" *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics* 1844.5 (2014): 1026-1033.

### Egg Yolk

Ben Wade, Michelle Cummins, Anthony Keyburn and Tamsyn M. Crowley. "[Isolation and detection of microRNA from the egg of chickens.](#)" *BMC Research Notes* 2016 9:283.

### Biofluids

Guyon, Léna, Anne-Claire Groo, and Aurélie Malzert-Fréon. "[Relevant Physicochemical Methods to Functionalize, Purify, and Characterize Surface-Decorated Lipid-Based Nanocarriers.](#)" *Molecular Pharmaceutics* (2020).

"Conjugation of PPACK (a short chain peptide that inhibits thrombin) to liposomes was investigated through HPLC quantification of uncoupled peptide recovered from the supernatant after centrifugation of predialysis **PPACK-liposomes mixed with Cleanascite™ lipid adsorption reagent.** This indirect quantification was performed at a wavelength of 215 nm (detection of amide bond)."

Graeme T Clark, Paul J Russell, and Steven Westwood. "[Modification without impact: a case study in clinical assay failure due to lipemia.](#)" *Bioanalysis*; 2012: 4,(12):1421-1428

### Organ Homogenates

Myerson, J., He, L., Lanza, G., Tollefsen, D. and Wickline, S. "[Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis.](#)" *Journal of Thrombosis and Haemostasis.*2011;9:1292-1300

### Red Blood Cells

Antunes RF; Brandao C; Maia M; Arosa FA. "[Red blood cells release factors with growth and survival bioactivities for normal and leukemic T cells.](#)" *Immunology and Cell Biology.*2011;89(1):111-21

### Tracheal Swab Samples

Li D, Wang J, Wang R, Li Y. "[A nanobeads amplified QCM immunosensor for the detection of avian influenza virus H5N1,](#)" *Biosensors and Bioelectronics.*2011;26(S10):4146-4154

### Tissue and Cell Culture

Alhamdani MS, Schroder C, Hoheisel JD. "[Analysis conditions for proteomic profiling of mammalian tissue and cell extracts with antibody microarrays.](#)" *Proteomics.*2010;10(17):3203-7

### Plasma/Serum

Dean, E. Danielle, et al. "[Interrupted glucagon signaling reveals hepatic  \$\alpha\$  cell axis and role for L-glutamine in  \$\alpha\$  cell proliferation.](#)" *Cell metabolism* 25.6 (2017): 1362-1373.

The article states "For lipid removal, **whole mouse serum was treated with Cleanascite™ reagent (Biotech Support Group, Monmouth Junction, NJ) prior to islet culture at a 1:1 ratio according to the vendor's protocol. Lipid removal was validated by HPLC to remove 99% of all phospholipids, cholesterol, and triglycerides...."**



## BIOTECH SUPPORT GROUP

Taylor, Steven W., et al. "[A high-throughput mass spectrometry assay to simultaneously measure intact insulin and C-peptide.](#)" Clinica Chimica Acta (2016). **Cleanascite™ is shown both to improve LC-MS measurements, and validated in accordance with CLIA '88 guidelines.**

McIntyre, John A., et al. "[Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease.](#)" *Autoimmunity*0 (2015): 1-8.

### Vaccine Research (Cholesterol Removal From Human Serum)

Kamtchoua, Thierry, Monica Bologna, Robert Hopfer, David Neveu, Branda Hu, Xiaohua Sheng, Nicolas Corde, Catherine Pouzet, Gloria Zimmerman, and Sanjay Gurunathan. [Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.](#) *Vaccine* (2012).

### Saliva

Lucy E. DesJardin [Isolation of M. tuberculosis RNA from Sputum](#) *Methods in Molecular Medicine*.2001;48:133-139

### Patents

Shiffman, Dov, et al. "[Methods for quantitation of insulin and c-peptide.](#)" U.S. Patent Application No. 15/942,188.

The application states "In some embodiments, serum is delipidated prior to quantitation by mass spectrometry. ... In some embodiments, **the delipidation reagent is Cleanascite™**".

### Yeast assays

Lifang, et al. [Balanced globin protein expression and heme biosynthesis improve production of human hemoglobin in Saccharomyces cerevisiae.](#) *Metabolic Engineering* (2013).

### For a complete list of all Cleanascite™ references, visit:

<http://www.biotechsupportgroup.com/References-s/138.htm#delipidation>

## CONTACT US

**We welcome your questions and comments regarding our products.**

**Tel:** 732-274-2866, 800-935-0628 (North America) Mon – Fri 9am-6pm EST.

**Fax:** 732-274-2899

**Email:** [sales@biotechsupportgroup.com](mailto:sales@biotechsupportgroup.com)

**Mail:** 1 Deer Park Drive, Suite M, Monmouth Junction, NJ 08852

**Web:** [www.biotechsupportgroup.com](http://www.biotechsupportgroup.com)